Empirical Finance LLC purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 6,605 shares of the medical research company’s stock, valued at approximately $1,149,000.
A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Toronto Dominion Bank grew its holdings in shares of Amgen by 11.0% during the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after purchasing an additional 27,726 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Amgen by 16.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after purchasing an additional 104,871 shares during the period. Putnam FL Investment Management Co. purchased a new stake in shares of Amgen during the 3rd quarter worth about $447,000. Wesbanco Bank Inc. grew its holdings in shares of Amgen by 6.5% during the 2nd quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock worth $18,393,000 after purchasing an additional 6,492 shares during the period. Finally, Moody Lynn & Lieberson LLC purchased a new stake in shares of Amgen during the 3rd quarter worth about $2,353,000. Institutional investors own 79.61% of the company’s stock.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.19% of the company’s stock.
Amgen, Inc. (NASDAQ:AMGN) opened at $189.75 on Wednesday. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23. The stock has a market capitalization of $136,402.42, a P/E ratio of 15.05, a price-to-earnings-growth ratio of 2.32 and a beta of 1.37. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the previous year, the company earned $2.89 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. equities research analysts anticipate that Amgen, Inc. will post 13.24 earnings per share for the current year.
Amgen declared that its Board of Directors has initiated a share buyback plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 205.45%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.